The addition of three new DMX customers in the last quarter is an important milestone for our innovative tool for drug model visualization. It is gratifying to see DMX progress from beta testing and first DMX commercial use, to the industry's recognition of the value of DMX in the Bio IT award, and now to the expansion of the DMX customer base.
HIV presents special therapeutic challenges to the drug development team, including resistance, complex pharmacokinetics, and patient compliance. Our modeling and simulation approach in HIV, as in other therapeutic domains, is to integrate relevant sub-models, estimate key parameters from trial data, and simulate candidate trial designs. The business benefits can include optimizing the design of the next trial or sequence of trials, better gono-go decisions, and strategies to optimize unavoidable tradeoffs such as that between patient compliance and difficult dosing.